ETFs & Funds
Home›ETFs & Funds›Equity Funds›Baron Health Care Fund highlights Edwards Lifesciences…
Baron Health Care Fund highlights Edwards Lifesciences growth runway
The fund reported a 11.99% gain in Q2 2026, and cited Edwards shares rising after updated Medicare coverage for TAVR.
Baron Capital’s Baron Health Care Fund highlighted Edwards Lifesciences Corporation (NYSE: EW) in its Q2 2026 investor letter, positioning the company’s structural heart disease therapies as a potential durable growth runway, according to Yahoo Finance.
In the quarter, the fund gained 11.99%, outperforming the Russell 3000 Health Care Index’s 10.48% and the Russell 3000 Index’s 15.44%, with Yahoo Finance also noting that strong stock selection across pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported performance.
The investor letter pointed to limited exposure to managed care stocks as a factor weighing on relative returns, while remaining positive on health care themes including improving biotechnology funding, acquisition activity, recovering managed care margins, and demand drivers tied to an aging population and chronic disease.
Yahoo Finance also reported that Edwards closed at $88.82 per share on August 3, 2026, with a one month return of -6.33% and a 12.09% gain over the past 52 weeks, and it attributed Edwards’ stock strength to solid first quarter results and an updated Medicare coverage decision for transcatheter aortic valve replacement, which could increase procedure volumes.